TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06757088

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cerebellar Stimulation Group (CbSG)
Description: For the Cerebellar Stimulation Group, active anodal electrode will be placed over the cerebellum bilaterally about 1-2 cm below the inion occipital protuberance, whereas the returning cathodal electrode will be placed on right buccinator muscle

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: M1 + Cerebellar Stimulation Group
Description: In M1, the anodal electrode will be placed over the M1 region while the cathodal electrode will be placed over the right contralateral supraorbital region whereas simultaneously for the CbSG, active anodal electrode will be placed over the cerebellum bilaterally about 1-2 cm below inion occipital protuberance, whereas the returning cathodal electrode will be placed on right buccinator muscle.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation Group
Description: In Sham stimulation, Electrodes will be placed according to M1 Stimulation i.e., the anodal electrode will be placed over M1 region while the cathodal electrode will be placed over the right contralateral supraorbital region.
Study: NCT06472869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NJOY ACE e-cigarette
Description: Patients will be provided with NJOY ACE electronic cigarettes and 5% nicotine e-liquid cartridges in tobacco flavor for 4 weeks and asked to use the electronic cigarette as a substitute for smoking combustible cigarettes during the 4 weeks
Study: NCT05687136

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT05777395

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maitland Oscillatory Mobilization
Description: Maitland Posteroanterior unilateral vertebral pressure and Maitland cervical rotation technique will be used.3 sets of 15 repetitions. Each set is of 30 seconds and each repetition is given for 2 seconds.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kaltenborn Sustained Stretch Mobilization
Description: Kaltenborn sustained stretch mobilizations. 3 sets of 15 repetitions for 3 seconds.~* Frequency: 3 times a week for 2 weeks. 6 sessions in total.~* Mobilizations will be performed in Grade 1 and then progressed to 2 and 3.~* Kaltenborn technique used will be atlas-axis rotation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Description: Moist heat, TENS, Neck Muscle Stretching, Neck muscle isometrics
Study: NCT05780060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of care, RPM and digital feedback
Description: Standard stroke follow up, RPM and a patient facing smartphone application containing real time BP feedback, educational models, treatment adherence push notification reminders, digital education and digital incentives (n=30). Outcomes will include recruitment, retention and follow up metrics, self-reported adherence to medication regimens and life-style recommendations, patient engagement with RPM data and patient-facing application, cost-effectiveness of the interventions and changes in blood pressure as well as biomarkers like LDL and Hemoglobin A1C.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care and RPM only
Description: Standard stroke clinic follow up and remote blood pressure monitoring (n=30). Outcomes will include qualitative patient and provider experiences with the TBIs including barriers and facilitators to the use of RPM and patient-facing application in the study population
Study: NCT05777395

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Description: Moist heat, TENS, Neck Muscle Stretching, Neck muscle isometrics
Study: NCT06032078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutera laser machine
Description: 1064nm Nd: YAG laser
Study: NCT05351931

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Salovum and SPC-flakes or corresponding placebo
Description: Salovum and SPC-flakes are foods approved for specific medical purposes.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Salovum and SPC-flakes or corresponding placebo
Description: Salovum and SPC-flakes are foods approved for specific medical purposes.
Study: NCT05930379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LSVT-Loud delivered by telerehabilitation
Description: LSVT-Loud treatment delivered by telerehabilitation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LSVT-Loud in the clinic
Description: LSVT-Loud delivered face-to-face in the clinic
Study: NCT04333485

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based Active Case Finding (HACF)
Description: Existing healthcare workers at the participating NTEP TB units will visit all patient homes at 6 and 12 months post-treatment completion. They will administer a standardized TB symptom screen questionnaire to treated TB cases and their household contacts (HHC). All those who screen positive will have a spot sputum taken at the home for microbiological testing at the TB unit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephonic Active Case Finding (TACF)
Description: Existing healthcare workers at the participating NTEP TB Units will administer a standardized TB symptom screen questionnaire to the index patient via telephone calls at 6 and 12 months post-treatment completion. The index patient will also be asked about any TB symptoms among household contacts (HHCs). If TB is suspected among any HH members, a home visit will be conducted and spot sputum specimens will be collected for microbiological testing at the TB unit.
Study: NCT05115695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional physiotherapy approach
Description: Traditional upper extremity strengthening and tonus regulation (weight shifting, weight bearing, active reaching in sitting exercises) exercises consisting of Neurodevelopmental Therapy (NDT-Bobath) approaches will be applied to the second group for 45 minutes, 3 days a week for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: muscle strengthening exercise/Proprioceptive Neuromuscular Facilitation (PNF)
Description: Muscle strengthening with scapular and upper extremity patterns of PNF exercise approach will be applied to the first group for 6 weeks, 3 days a week, 30 minutes a day.
Study: NCT06397495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Cervical region manual therapy training will be given with flipped learning models.
Study: NCT05854914

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Use of hypnosis videos
Description: Hypnosis on smartphone will be used to manage pain for emergent coelioscopy surgery of patients with acute and complicated appendicitis, with generalized peritonitis
Study: NCT05700383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GetActive-Fitbit
Description: GetActive-Fitbit is an adaptation of the original GetActive-Fitbit program, a mind-body program for the unique needs of individuals with chronic musculoskeletal pain that incorporates activity skills to help individuals improve all aspects of physical function. The GetActive-Fitbit sessions address mind-body skills (e.g., mindfulness, deep breathing, self-compassion), walking skills (e.g., step goals, quota-based pacing), and skills to change thinking (e.g., identify unhelpful thoughts about pain and activity, challenging thoughts). The format is a 10-week program delivered in-person with weekly group sessions and home practice of skills and walking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living for Pain
Description: Healthy Living for Pain is an active intervention that will be dose, attention, and time matches to the GetActive-Fitbit program. Healthy Living for Pain is an adaptation of the Health Enhancement Program, developed by Dr. Vranceanu and colleagues from Stony Brook, with adjustments for patients with chronic musculoskeletal pain. The Healthy Living for Pain sessions provide educational information on chronic musculoskeletal pain, the role of sleep and nutrition, physical activity, healthcare management, medication use, and social connection. The format is a 10-week program delivered in-person with weekly group sessions and home practice journaling.
Study: NCT06169813

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Description: NRT (daily patches and lozenges). NRT strength will be according to the established dosing guidelines for tobacco treatment. NRT is the standard of care in tobacco treatment and helped reduce CPD in prior trials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-Cigarette (EC)
Description: EC with single-use pods. Nicotine - 48 mg/ ml (4.8% nicotine) concentration.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Each participant will receive up to 5-motivational counseling sessions. The first session will also include orientation of EMA/EMI texting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Each participant will receive up to 5-motivational counseling sessions. The first session will also include orientation of EMA/EMI texting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Each participant will receive up to 5-motivational counseling sessions. The first session will also include orientation of EMA/EMI texting.
Study: NCT06208774

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided PENG or ISBP block
Description: The diaphragmatic excursion will be measured in the supine position before the block and after surgery. A curvilinear US probe (5-7 MHz) will be placed at the subcostal area in the anterior axillary line, below the costal margin of the eighth and ninth ribs. The probe will be directed medially, cephalad, and dorsally to make the US beam reach the posterior third of the diaphragm perpendicularly. The probe will then be scanned along the long axis of the intercostal spaces, using the liver as the acoustic window on the right side and the spleen as on the left side. M-mode sampling line will be positioned perpendicularly to the diaphragm, and the diaphragmatic excursions could be measured during quiet and deep breathing.The measurement will be repeated three times, and the average value will be taken. After measurement of diaphragmatic excursion, patients will receive either a PENG block or an LV-ISBP block before induction of general anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided PENG or ISBP block
Description: The diaphragmatic excursion will be measured in the supine position before the block and after surgery. A curvilinear US probe (5-7 MHz) will be placed at the subcostal area in the anterior axillary line, below the costal margin of the eighth and ninth ribs. The probe will be directed medially, cephalad, and dorsally to make the US beam reach the posterior third of the diaphragm perpendicularly. The probe will then be scanned along the long axis of the intercostal spaces, using the liver as the acoustic window on the right side and the spleen as on the left side. M-mode sampling line will be positioned perpendicularly to the diaphragm, and the diaphragmatic excursions could be measured during quiet and deep breathing.The measurement will be repeated three times, and the average value will be taken. After measurement of diaphragmatic excursion, patients will receive either a PENG block or an LV-ISBP block before induction of general anesthesia.
Study: NCT05687136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuvusertib
Description: Given PO
Study: NCT06429449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax attaches to a protein called Bcl-2. This protein is present in high amounts in CLL cancer cells, where it helps the cells survive for longer in the body and makes them resistant to cancer medicines. By attaching to Bcl-2 and blocking its actions, venetoclax causes the death of cancer cells and thereby slows down progression of the disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax attaches to a protein called Bcl-2. This protein is present in high amounts in CLL cancer cells, where it helps the cells survive for longer in the body and makes them resistant to cancer medicines. By attaching to Bcl-2 and blocking its actions, venetoclax causes the death of cancer cells and thereby slows down progression of the disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax attaches to a protein called Bcl-2. This protein is present in high amounts in CLL cancer cells, where it helps the cells survive for longer in the body and makes them resistant to cancer medicines. By attaching to Bcl-2 and blocking its actions, venetoclax causes the death of cancer cells and thereby slows down progression of the disease.
Study: NCT06253065

Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial intelligence (AI)-based diagnostic model (developed)
Description: Collect pathological slides of resected lymph nodes of the enrolled patients. Digitise these slides into whole-slide images (WSIs). Analyze the WSIs using the AI model to generate diagnostic results (with or without lymphatic metastasis). No intervention to patients would be performed in this diagnostic test study.
Study: NCT05354128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thrombolytic
Description: Standard intravenous thrombolysis.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: percutaneous coronary stenting
Description: Percutaneous coronary stenting
Study: NCT06429449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax attaches to a protein called Bcl-2. This protein is present in high amounts in CLL cancer cells, where it helps the cells survive for longer in the body and makes them resistant to cancer medicines. By attaching to Bcl-2 and blocking its actions, venetoclax causes the death of cancer cells and thereby slows down progression of the disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: An analog of the pyrimidine nucleoside cytidine, has effects on cell differentiation, gene expression, and deoxyribonucleic acid (DNA) synthesis and metabolism, and causes cytotoxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: An analog of the pyrimidine nucleoside cytidine, has effects on cell differentiation, gene expression, and deoxyribonucleic acid (DNA) synthesis and metabolism, and causes cytotoxicity.
Study: NCT04932785

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular diet
Description: Regular diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clear Liquid Diet
Description: Clear Liquid Diet
Study: NCT05809271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA 120 mg + MDMA 60 mg
Description: An oral dose of 120 mg racemic MDMA will be administered followed by a second dose of 60 mg racemic MDMA two hours later.
Study: NCT06429449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: An analog of the pyrimidine nucleoside cytidine, has effects on cell differentiation, gene expression, and deoxyribonucleic acid (DNA) synthesis and metabolism, and causes cytotoxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: An analog of the pyrimidine nucleoside cytidine, has effects on cell differentiation, gene expression, and deoxyribonucleic acid (DNA) synthesis and metabolism, and causes cytotoxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Mitoxantrone Injection, USP (concentrate) is a synthetic antineoplastic anthracenedione for intravenous use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Mitoxantrone Injection, USP (concentrate) is a synthetic antineoplastic anthracenedione for intravenous use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Mitoxantrone Injection, USP (concentrate) is a synthetic antineoplastic anthracenedione for intravenous use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Mitoxantrone Injection, USP (concentrate) is a synthetic antineoplastic anthracenedione for intravenous use.
Study: NCT04876222

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acute CAG
Description: The patient is triaged directly to the catheterization laboratory for acute evaluation including ECHO, acute CAG and PCI if indicated according to guidelines.
Study: NCT06331429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EmoTiCare
Description: The EMOTICARE technological platform intervenes in users through a serious game, i.e. a video game whose main purpose is to teach or provide the player with certain skills that serve to achieve a higher purpose than the game itself.~The game works in 6 areas, each of which refers to one of the variables that are analysed or considered important in the adaptation to the disease: Area 1. Psychoeducation of DM1; 2. Emotional awareness and expression; 3. Emotional regulation; 4. Problem solving; 5. Self-esteem and identity;6. Social skills and communication
Study: NCT05960240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-101
Description: AB-101 is an oral small molecule PD-L1 checkpoint inhibitor being developed for the treatment of chronic infection with HBV in combination with other agents.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-101
Description: AB-101 is an oral small molecule PD-L1 checkpoint inhibitor being developed for the treatment of chronic infection with HBV in combination with other agents.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-101
Description: AB-101 is an oral small molecule PD-L1 checkpoint inhibitor being developed for the treatment of chronic infection with HBV in combination with other agents.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo is any treatment that has no active properties, such as a sugar pill. We will use matching placebo for this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo is any treatment that has no active properties, such as a sugar pill. We will use matching placebo for this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo is any treatment that has no active properties, such as a sugar pill. We will use matching placebo for this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide Analogue
Description: Nucleos(t)ide analogues (NUCs) are the standard and mostly lifelong treatment for chronic HBeAg-negative hepatitis B.
Study: NCT05389761

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fibroDAO®
Description: One DAO enzyme capsule is taken with water 20 minutes before each meal, 3 times a day. DAO enzyme capsules contains 0.3 mg DAO enzyme divided into 2 white/beige tablets (each gastro-resistant tablet contains 0.15 mg DAO enzyme) and 80 mg magnesium divided into 2 lilac tablets (each immediate-release tablet contains 40 mg of Mg).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo capsule is taken with water 20 minutes before each meal, 3 times a day. Placebo capsules consist of microcrystalline cellulose and gelatin capsules with the same shape, size and colour as the DAO enzyme.
Study: NCT04783506

Intervention type: OTHER
Intervention: Observational Study
Description: There is no intervention provided by this study. Observed for 12-month period using questionnaires and study visits.

Intervention type: OTHER
Intervention: Observational Study
Description: There is no intervention provided by this study. Observed for 12-month period using questionnaires and study visits.

Intervention type: OTHER
Intervention: Observational Study
Description: There is no intervention provided by this study. Observed for 12-month period using questionnaires and study visits.
Study: NCT05687435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Changyanning tablet
Description: Changyanning Tablet is produced by Jiangxi Kang'enbei Traditional Chinese Medicine Co., Ltd，composed of Euphorbia humifusa, golden ear grass, camphor tree root, Elsholtzia splendens and maple leaves. It is mainly used for the treatment of acute and chronic intestinal diseases caused by various reasons.~If the symptoms of the subject become worse and unbearable during the study period, it is allowed to add Pinaverium Bromide to the patient according to the specific situation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Changyanning tablet placebo
Description: Changyanning Tablet placebo is produced by Jiangxi Kang'enbei Traditional Chinese Medicine Co., Ltd. Changyanning Tablet placebo has the same appearance, smell, taste, specifications and packaging with Changyanning Tablet, but does not contain active pharmaceutical ingredients.~If the symptoms of the subject become worse and unbearable during the study period, it is allowed to add Pinaverium Bromide to the patient according to the specific situation.
Study: NCT05809271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA 120 mg + placebo
Description: An oral dose of 120 mg racemic MDMA will be administered followed by a placebo two hours later.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An oral placebo will be administered followed by a placebo two hours later.
Study: NCT05224609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Single 100mg oral dose anti-cancer agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Single 100mg oral dose anti-cancer agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Single 100mg oral dose anti-cancer agent
Study: NCT05594706

Intervention type: OTHER
Intervention: Measurement of blood levels of 1,5-anhydroglucitol
Description: Measurement of blood levels of 1,5-anhydroglucitol

Intervention type: OTHER
Intervention: Measurement of blood levels of 1,5-anhydroglucitol
Description: Measurement of blood levels of 1,5-anhydroglucitol